Clinical trial · Observational
O-GlcNAcylation Induced HMGB1 Signalling
O-GlcNAcylation Induced HMGB1 Signaling as a Molecular Switch for Immune Escape in Esophageal Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates how HMGB1 compartmentalisation and O-GlcNAcylation regulate inflammatory signalling, autophagy, and immune escape in cancer. Our research focuses on HMGB1, a key mediator of inflammation and immune regulation. Because extracellular HMGB1 and related cytokines are detectable in blood, circulating plasma biomarkers may serve as systemic surrogates of tumour-immune microenvironment (TIME) biology. Spatial profiling technologies-such as multiplex immunofluorescence (mIF) and GeoMx Digital Spatial Profiling (DSP)-enable precise mapping of HMGB1 localisation, O-GlcNAcylation status, and immune cell organisation within tumour tissues. Integrating these spatial tissue features with plasma cytokine signatures provides a mechanistic and clinically translatable approach for recurrence prediction. This study aims to determine whether baseline and early-on-treatment plasma cytokine profiles can predict recurrence in patients with esophageal squamous cell carcinoma (ESCC), and to evaluate how these circulating immune mediators correspond to spatially resolved TIME features.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma (ESCC) | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| specimen collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Study Group
- description
- This study will enroll one single cohort of ESCC patients, who will undergo specimen collection at predefined clinical timepoints corresponding to major disease stages: (1) Baseline at diagnosis, (2) On-treatment, and (3) At recurrence or metastasis. All participants are governed by the same inclusion and exclusion criteria. Data are analyzed longitudinally for patients who contribute specimens across multiple timepoints.
- interventionNames
- Other: specimen collection
Primary outcomes (1)
- measure
- Recurrence-Free Survival (RFS)
- timeFrame
- 5 years
- description
- Recurrence-free survival is defined as the time from diagnosis to the first documented recurrence of esophageal squamous cell carcinoma (ESCC). This outcome will be analysed in relation to baseline and early on-treatment plasma biomarkers, including cytokines, chemokines, and DAMP-related markers, to evaluate their prognostic value in predicting recurrence risk.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years. * Histologically confirmed ESCC * Able to provide written informed consent. * Able to comply with study procedures. Exclusion Criteria: * Withdrawal of consent. * Irreversible coagulation disorders preventing clinically indicated biopsies. * With other co-existing malignancy
References
Publications (0)
Data not yet available